Nardelli Dean T, Munson Erik L, Callister Steven M, Schell Ronald F
University of Wisconsin, Department of Medical Microbiology & Immunology, Wisconsin State Laboratory of Hygiene, 465 Henry Mall, Madison, WI 53706, USA.
Future Microbiol. 2009 May;4(4):457-69. doi: 10.2217/fmb.09.17.
The development of a vaccine for Lyme disease was intensely pursued in the 1990s. However, citing a lack of demand, the first human Lyme disease vaccine was withdrawn from the market less than 5 years after its approval. The public's concerns about the vaccine's safety also likely contributed to the withdrawal of the vaccine. Nearly a decade later, no vaccine for human Lyme disease exists. The expansion of Lyme disease's endemic range, as well as the difficulty of diagnosing infection and the disease's steady increase in incidence in the face of proven preventative measures, make the pursuit of a Lyme disease vaccine a worthwhile endeavor. Many believe that the negative public perception of the Lyme disease vaccine will have tarnished any future endeavors towards its development. Importantly, many of the drawbacks of the Lyme disease vaccine were apparent or foreseeable prior to its approval. These pitfalls must be confronted before the construction of a new, effective and safe human Lyme disease vaccine.
20世纪90年代，人们积极研发莱姆病疫苗。然而，由于缺乏需求，首款人类莱姆病疫苗在获批不到5年后就被撤出市场。公众对该疫苗安全性的担忧也可能促使了疫苗的撤市。近十年后，仍不存在用于人类的莱姆病疫苗。莱姆病流行范围的扩大、感染诊断的困难以及在有已证实的预防措施的情况下该病发病率的持续上升，使得研发莱姆病疫苗成为一项值得努力的工作。许多人认为，公众对莱姆病疫苗的负面看法将损害未来在其研发方面的任何努力。重要的是，莱姆病疫苗的许多缺点在获批之前就已明显或可预见。在构建一种新的、有效且安全的人类莱姆病疫苗之前，必须正视这些问题。
